16 November 2021 - Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to a single drug alone: Humira.
The Institute for Clinical and Economic Review today published its latest report on unsupported price increases of prescription drugs in the United States.